(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.49% $ 1.025
Live Chart Being Loaded With Signals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...
Stats | |
---|---|
Объем за сегодня | 4.85M |
Средний объем | 1.64M |
Рыночная капитализация | 210.38M |
EPS | $0 ( 2024-03-20 ) |
Дата следующего отчета о доходах | ( $0 ) 2024-05-07 |
Last Dividend | $0.150 ( 2012-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.85 |
ATR14 | $0.0510 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-27.75 |
Last 97 transactions |
Buy: 24 888 642 | Sell: 15 180 768 |
Объем Корреляция
Spectrum Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
IRMD | 0.941 |
IDCC | 0.939 |
SLMBP | 0.939 |
DRNA | 0.933 |
PRAA | 0.924 |
MESA | 0.923 |
PIRS | 0.923 |
GALT | 0.922 |
HLIO | 0.92 |
IOAC | 0.919 |
10 Самые отрицательные корреляции | |
---|---|
GMII | -0.923 |
AVIR | -0.911 |
TUEM | -0.907 |
JRJC | -0.896 |
AFYA | -0.896 |
EAR | -0.887 |
GSMG | -0.885 |
DTSS | -0.883 |
ATSG | -0.881 |
GOEV | -0.88 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Spectrum Pharmaceuticals Корреляция - Валюта/Сырье
Spectrum Pharmaceuticals Финансовые показатели
Annual | 2022 |
Выручка: | $10.11M |
Валовая прибыль: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2022 |
Выручка: | $10.11M |
Валовая прибыль: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2021 |
Выручка: | $0.00 |
Валовая прибыль: | $0.00 (0.00 %) |
EPS: | $-1.020 |
FY | 2020 |
Выручка: | $0.00 |
Валовая прибыль: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Spectrum Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-18 |
Last Dividend | $0.150 | 2012-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.150 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.150 | 1.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.400 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.334 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.193 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.71 | 0.800 | 1.449 | 1.159 | [1 - 3] |
quickRatioTTM | 2.31 | 0.800 | 1.124 | 0.899 | [0.8 - 2.5] |
cashRatioTTM | 1.347 | 1.500 | 3.63 | 5.44 | [0.2 - 2] |
debtRatioTTM | 0.275 | -1.500 | 5.42 | -8.12 | [0 - 0.6] |
interestCoverageTTM | -19.33 | 1.000 | -8.27 | -8.27 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.161 | -0.322 | [0 - 20] |
debtEquityRatioTTM | 1.105 | -1.500 | 5.58 | -8.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.889 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.481 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.239 | 0.800 | -1.740 | -1.392 | [0.5 - 2] |
Total Score | -3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.75 | 1.000 | -0.682 | 0 | [1 - 100] |
returnOnEquityTTM | -1.193 | 2.50 | -9.24 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.107 | -0.322 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.583 | 1.500 | 9.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.51 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.111 |
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа